A phase I trial examined the efficacy of tirzepatide in reducing energy intake and appetite in non-diabetic adults with obesity. Tirzepatide demonstrated significant reductions in energy intake, cravings for high-fat and sweet foods, and disinhibition in overeating within 3 weeks of treatment. Functional MRI revealed modulation of brain responses to food cues. The drug showed gastrointestinal adverse effects but produced significant weight loss. Comparisons with liraglutide indicated superior efficacy of tirzepatide in appetite control. The study provides mechanistic insights into the drug's clinical efficacy for obesity treatment.

Source: Nature Medicine